mRNA Therapeutics Contract Development & Manufacturing Organization Market Size | key Companies
mRNA Therapeutics Contract Development & Manufacturing Organization Market Size and Growth
The global mRNA therapeutics contract development & manufacturing organization market size was valued at USD 5.19 billion in 2023 and is anticipated to reach around USD 15.15 billion by 2033, growing at a CAGR of 11.31% from 2024 to 2033.
mRNA Therapeutics Contract Development & Manufacturing Organization Market Key Takeaways
mRNA Therapeutics Contract Development & Manufacturing Organization Market Growth
Growth in the market can be attributed to the increasing burden of infectious diseases & cancer cases, rising mRNA vaccine development, shifting clinical requirements, and digitalization that have revolutionized vaccine development & other therapeutic applications. In addition, mRNA therapeutics manufacturing is driven by growing investments and an increasing number of CDMOs. Furthermore, Research & Development (R&D) activities and preclinical studies have augmented the market demand.
The COVID-19 pandemic positively impacted the market expansion by creating an urgent need for vaccines and a high amount of funding for developing and manufacturing mRNA-based COVID-19 vaccines. In addition, as mRNA vaccines offer a strong defense against new strains of the SARS-COVID-19 virus, demand is still high post-pandemic. The biopharmaceutical companies partnered with the CDMO during the mRNA COVID-19 vaccine (mRNA-1273). Such partnerships are likely to have supported the market during the pandemic. mRNA technologies have emerged as a unique and effective strategy to generate new medications that have the potential to change existing therapies or target difficult-to-treat indications, such as respiratory, cardiac, metabolic, and autoimmune illnesses, as well as cancer.
Advances in mRNA technology and cellular delivery methods, with their low cost, ease of manufacture, and capacity to target previously unknown pathways, have endless potential to revolutionize medicine. These factors of mRNA are increasing the demand for mRNA CDMO services, thereby promoting market growth. The pharmaceutical and biotech industries are key end-users for CDMOs as they offer potential capabilities and cost savings over in-house manufacturing. Due to their inability to effectively produce and develop treatments, small- and mid-sized CDMOs contract out their development and manufacturing needs. This element is anticipated to boost market expansion.
mRNA Therapeutics Contract Development & Manufacturing Organization Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 5.78 Billion |
| Market Size by 2033 | USD 15.15 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 11.31% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Application, indication, end-use, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Danaher (Aldevron); Biomay AG; Bio-Synthesis, Inc.; eTheRNA; Kaneka Eurogentec S.A.; TriLink BioTechnologies; ApexBio Technology; BioNTech SE; BioCina; Lonza; Recipharm AB; Novo Holdings (Catalent, Inc.); Samsung Biologics |
Application Insights
On the basis of application segment, the market is segregated into viral vaccines, protein replacement therapies, and cancer immunotherapies. The viral vaccines segment led the market, accounting for 100% of global revenue in 2023. The demand in the segment can be attributed to established technology, the wide applicability of viral vaccines, and the launch of various mRNA-based vaccines to control the spread of the COVID-19 virus. For instance, in January 2023, Moderna announced mRNA-1345, an investigational respiratory syncytial virus vaccine. Phase 3 trial involves studying the coadministration of flu vaccine and COVID-19 (mRNA-1083) for older adults and is fully enrolled.
This phase 3 study data is expected in 2024. Furthermore, expanding the mRNA vaccine pipeline is expected to drive market growth in the coming decade. The development of mRNA vaccines to treat various infectious diseases is also increasing. Companies have begun including vaccinations for various diseases, such as influenza, Zika, and Cytomegalovirus (CMV), in their pipelines along with COVID-19. This trend indicates the versatility of mRNA vaccines. Such factors are anticipated to drive market growth. The cancer immunotherapies segment is anticipated to grow at the fastest CAGR over the forecast period.
The growth is attributed to the increasing cancer prevalence and investments to develop novel therapies to combat this growing prevalence. Cancer immunotherapies, including mRNA-based approaches, are showing significant promise and attracting considerable attention in oncology. mRNA cancer vaccines represent a potent and adaptable approach to immunotherapy. The primary advantage of mRNA cancer immunotherapies is their potent immunogenicity, which triggers strong cell-mediated and humoral immune responses, thus contributing to market growth.
Indication Insights
On the basis of indication segment, the market is segregated into infectious diseases, metabolic & genetic diseases, and cardiovascular & cerebrovascular diseases. The infectious diseases segment dominated the market in 2023, accounting for a revenue share of 100.00%. The increasing adoption of mRNA-based vaccines, a high number of candidates entering clinical trials for various infectious diseases, and the COVID-19 outbreak in late 2019 have led to the dominance of this segment. Moreover, the prevalence of infectious diseases has long been a global health problem, and mRNA therapies have emerged as promising tools in combating these diseases.
mRNA therapeutics promises growth regarding infectious diseases, and the market represents a dynamic & fast-growing segment with unique advantages and growth potential. The growing incidence of respiratory diseases has highlighted the need for rapid and flexible vaccine development. For instance, in February 2024, ReCode Therapeutics mentioned that the first volunteer had been dosed in a Phase 1 clinical study of RCT2100. It is an inhaled investigational therapy based on mRNA for cystic fibrosis that is focused on 10-13% of patients with nonsense mutations who do not experience any side effects with approved CFTR modulators.
The metabolic & genetic segment is anticipated to grow at a rapid CAGR of 11.65% over the forecast period. This segment includes cancer and other genetic diseases. The segment growth is attributed to the subsequent number of products under development for these applications. For instance, in February 2023, Moderna entered into an agreement with Life Edit Therapeutics to address genetic diseases using mRNA-based gene editing. This partnership combines Moderna’s mRNA platform with Life Edit’s specialized gene editing capabilities, including an emerging and precise gene editing technique called base editing.
End-use Insights
On the basis of the end-uses, the market is segregated into biotech companies, pharmaceutical companies, and government & academic research institutes. The biotech companies segment dominated the market in 2023 due to the growing need for therapeutics for COVID-19 and increasing trend of outsourcing end-to-end services, especially among small- and mid-sized biotechnology companies that lack expertise in mRNA development. Moreover, strategic initiatives, such as partnerships and collaborations, with CDMO have helped biotech companies to generate profitable revenues. For instance, in September 2023, PackGene Biotech Inc. and Kudo Biotechnology formed a strategic partnership to offer high-quality mRNA manufacturing services for drug and vaccine development.
This collaboration encompasses comprehensive support for mRNA development, gene-to-mRNA conversion, Lipid Nanoparticle (LNP) formulation development, encapsulation, and production of finished drug products. The government & research institutes segment is expected to grow at the fastest CAGR of 11.55% from 2024 to 2030. The segment growth is due to rising investment by government bodies to develop novel therapies for chronic diseases and an elevated interest in healthcare post the major challenges faced due to the pandemic. For instance, in March 2023, the U.S. government invested USD 31.9 billion in research and procurement of mRNA vaccines. The investment will support the development, production & purchasing of mRNA-based COVID-19 vaccines through the National Institutes of Health to the Department of Defense. It aimed to enhance overall support for mRNA COVID-19 vaccine production.
Regional Insights
The North America mRNA therapeutics contract development & manufacturing organization market accounted for the largest share of 37.85% of the global revenue in 2023. The market growth is driven by established CDMOs, increasing clinical trials, and a growing prevalence of infectious diseases, respiratory diseases, and cardiovascular & cerebrovascular diseases in North America. For instance, in February 2024, Arcturus Therapeutics and CSL announced the results of a follow-up on the ARCT-154 booster dose Phase 3 study. It was the first sa-mRNA COVID-19 vaccine approved globally and can be administered at one-sixth the dose of Comirnaty (5 μg vs 30 μg).
U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Trends
The mRNA therapeutics contract development & manufacturing organization market in the U.S. held the largest share in 2023. The country accounts for the highest share of the North America regional market, as many pharmaceutical and life sciences companies are present in this country. Growing interest in clinical trials and the benefits of live biotherapeutics in treating rare diseases drive the development of new & novel drugs. Moreover, a well-established regulatory framework provides new opportunities for companies to develop and manufacture products with wide applications & target populations and improved knowledge of the importance of mRNA in terms of therapeutics.
Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Trends
The Europe mRNA therapeutics contract development & manufacturing organization market is expected to grow significantly. Due to the COVID-19 pandemic, vaccine developers entered into strategic agreements with contract development and manufacturing service providers to meet the urgent global demand for mRNA-based vaccines, which led to significant growth in the outsourcing industry. Moreover, manufacturing mRNA therapeutics is complex, cost-intensive, and requires skilled professionals. Thus, several small- to medium-sized companies rely on CDMO to produce mRNA-synthesized products to innovate new mRNA therapeutics.
The mRNA therapeutics contract development & manufacturing organization market in Germany held the largest share in 2023 owing to a substantial number of providers offering mRNA therapeutics and initiatives undertaken to expand the scope of these tools. For instance, in February 2023, BioNTech announced that it would invest USD 43 million to establish an mRNA manufacturing facility in Germany. Therefore, the market is expected to be driven by rising investments in mRNA technology.
The UK mRNA therapeutics contract development & manufacturing organization market is anticipated to grow over the forecast period. Increasing government initiatives to support mRNA therapeutics development and accelerate clinical trials for mRNA immune therapies drive market growth. For instance, in January 2023, BioNTech announced a strategic collaboration with the UK government to deliver personalized mRNA cancer immunotherapies to around 10,000 patients by 2030. This multiyear partnership focuses on three key strategic pillars: cancer immunotherapies, vaccines for infectious diseases, and expanding BioNTech's presence in the UK.
Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Trends
The mRNA therapeutics contract development & manufacturing organization market in Asia Pacific is expected to grow at a CAGR of 10.84% from 2024 to 2033. Key factors contributing to this growth are increasing R&D investments, the rising prevalence of diseases that can be targeted by mRNA therapies, and advancements in technology.
The China mRNA therapeutics contract development & manufacturing organization market is expected to grow over the forecast period. Significant investments in expanding and upgrading manufacturing infrastructure for mRNA therapies in China are expected to drive market growth in the near future.
The mRNA therapeutics contract development & manufacturing organization market in Japan held the largest share in 2023 due to growing initiatives to set up drug discovery infrastructure in Japan, rising investments by private & public sectors, and strategic initiatives, such as mergers & acquisitions, by key companies. For instance, in August 2022, Ricoh Company Ltd. announced the establishment of a Ricoh Biomedical Startup Fund to support mRNA drug R&D in Japan.
The India mRNA therapeutics contract development & manufacturing organization market is anticipated to grow at the fastest CAGR over the forecast period. This growth can be attributed to the availability of a large pool of skilled scientists, researchers, and professionals in biotechnology & pharmaceuticals.
mRNA Therapeutics Contract Development & Manufacturing Organization Market Top Key Companies:
Recent Developments
mRNA Therapeutics Contract Development & Manufacturing Organization Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the mRNA Therapeutics Contract Development & Manufacturing Organization market.
By Application
By Indication
By End-use
By Region
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Regional Scope
1.2 Estimates And Forecast Timeline
1.3 Market Definition
1.4 Research Methodology
1.5 Information Procurement
1.5.1 Information Analysis
1.5.2 Market Formulation & Data Visualization
1.5.3 Data Validation & Publishing
1.6 Research Scope And Assumptions
1.6.1 Commodity Flow Analysis
1.6.2 Top Down Market Estimation
1.6.3 Region/Country Based Segment Share Calculation.
1.6.4 Multivariate Analysis
1.6.5 Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: CAGR Calculation
1.7 List of Secondary Sources
1.8 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Segment Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.1.2.1 Global Recombinant Protein Therapeutics CDMO Market
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rapid Adoption Of Mrna In Vaccine Development
3.2.1.2 Multiple Research Efforts On Mrna Therapeutics
3.2.1.3 Major Funding For Mrna Research
3.2.2 Market Restraint Analysis
3.2.2.1 Availability of Low-cost Substitute Therapies
3.2.2.2 High Research Cost
3.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 Pestel Analysis
3.4 COVID-19 Impact Analysis
Chapter 4 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Application Analysis
4.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Application Segment: Key Takeaways
4.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Application Movement Analysis
4.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by Application (USD Million)
4.4 Viral Vaccines
4.4.1 Viral Vaccines Market, 2021 - 2033
4.5 Protein Replacement Therapies
4.5.1 Protein Replacement Therapies Market, 2021 - 2033
4.6 Cancer Immunotherapies
4.6.1 Cancer Immunotherapies Market, 2021 - 2033
Chapter 5 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Indication Analysis
5.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Indication Segment: Key Takeaways
5.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Indication Movement Analysis
5.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by Indication (USD Million)
5.4 Infectious Diseases
5.4.1 Infectious Diseases Market, 2021 - 2033
5.5 Metabolic & Genetic Diseases
5.5.1 Metabolic & Genetic Diseases Market, 2021 - 2033
5.6 Cardiovascular & Cerebrovascular Diseases
5.6.1 Cardiovascular & Cerebrovascular Diseases Market, 2021 - 2033
Chapter 6 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: End-use Analysis
6.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by End-use Segment: Key Takeaways
6.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: End-use Movement Analysis
6.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by End-use (USD Million)
6.4 Biotech Companies
6.4.1 Biotech Companies Market, 2021 - 2033
6.5 Pharmaceutical Companies
6.5.1 Pharmaceutical Companies Market, 2021 - 2033
6.6 Government & Academic Research Institutes
6.6.1 Government & Academic Research Institutes Market, 2021 - 2033
Chapter 7 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Regional Analysis
7.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Regional Segment: Key Takeaways
7.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO): Market Share Analysis, 2023 & 2030
7.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO): Market Estimates and Forecast, by Region (USD Million)
7.4 North America
7.4.1 North America Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.4.2 U.S.
7.4.2.1 Key Country Dynamics
7.4.2.2 Competitive Scenario
7.4.2.3 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.4.3 Canada
7.4.3.1 Key Country Dynamics
7.4.3.2 Competitive Scenario
7.4.3.3 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.5 Europe
7.5.1 Europe Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.5.2 UK
7.5.2.1 Key Country Dynamics
7.5.2.2 Competitive Scenario
7.5.2.3 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.5.3 Germany
7.5.3.1 Key Country Dynamics
7.5.3.2 Competitive Scenario
7.5.3.3 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.5.4 France
7.5.4.1 Key Country Dynamics
7.5.4.2 Competitive Scenario
7.5.4.3 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.5.5 Italy
7.5.5.1 Key Country Dynamics
7.5.5.2 Competitive Scenario
7.5.5.3 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.5.6 Spain
7.5.6.1 Key Country Dynamics
7.5.6.2 Competitive Scenario
7.5.6.3 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.5.7 Denmark
7.5.7.1 Key Country Dynamics
7.5.7.2 Competitive Scenario
7.5.7.3 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.5.8 Sweden
7.5.8.1 Competitive Scenario
7.5.8.2 Key Country Dynamics
7.5.8.3 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.5.9 Norway
7.5.9.1 Key Country Dynamics
7.5.9.2 Competitive Scenario
7.5.9.3 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.6 Asia Pacific
7.6.1 Asia Pacific Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (Usd Million
7.6.2 Japan
7.6.2.1 Key Country Dynamics
7.6.2.2 Competitive Scenario
7.6.2.3 Japan Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.6.3 China
7.6.3.1 Key Country Dynamics
7.6.3.2 Competitive Scenario
7.6.3.3 China Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.6.4 India
7.6.4.1 Key Country Dynamics
7.6.4.2 Competitive Scenario
7.6.4.3 India Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.6.5 Australia
7.6.5.1 Key Country Dynamics
7.6.5.2 Competitive Scenario
7.6.5.3 Australia Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.6.6 South Korea
7.6.6.1 Key Country Dynamics
7.6.6.2 Competitive Scenario
7.6.6.3 South Korea Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.6.7 Indonesia
7.6.7.1 Key Country Dynamics
7.6.7.2 Competitive Scenario
7.6.7.3 Indonesia Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.7 Latin America
7.7.1 Latin America Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.7.2 Brazil
7.7.2.1 Key Country Dynamics
7.7.2.2 Competitive Scenario
7.7.2.3 Brazil Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.7.3 Mexico
7.7.3.1 Key Country Dynamics
7.7.3.2 Competitive Scenario
7.7.3.3 Mexico Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.7.4 Argentina
7.7.4.1 Key Country Dynamics
7.7.4.2 Competitive Scenario
7.7.4.3 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.8 MEA
7.8.1 Mea Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.8.2 South Africa
7.8.2.1 Key Country Dynamics
7.8.2.2 Competitive Scenario
7.8.3 Saudi Arabia
7.8.3.1 Key Country Dynamics
7.8.3.2 Competitive Scenario
7.8.3.3 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.8.4 UAE
7.8.4.1 Key Country Dynamics
7.8.4.2 Competitive Scenario
7.8.4.3 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
7.8.5 Kuwait
7.8.5.1 Key Country Dynamics
7.8.5.2 Competitive Scenario
7.8.5.3 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
Chapter 8 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Competitive Landscape
8.1. Market Participant Categorization
8.2. Market Position Analysis, 2022/2023 (Heat Map Analysis)
8.3. Company Profiles
8.3.1. Strategy Mapping
8.3.2. Service Launches
8.3.3. Acquisition
8.3.4. Partnerships/Agreements/Collaboration
8.3.5. Expansions
8.4. Vendor Landscape
8.4.1. Key company market share analysis, 2023
8.4.2. Danaher (Aldevron)
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product/service benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Biomay AG
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product/service benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Bio-Synthesis, Inc.
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product/service benchmarking
8.4.4.4. Strategic initiatives
8.4.5. eTheRNA
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product/service benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Kaneka Eurogentec S.A.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product/service benchmarking
8.4.6.4. Strategic initiatives
8.4.7. TriLink BioTechnologies
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product/service benchmarking
8.4.7.4. Strategic initiatives
8.4.8. ApexBio Technology
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product/service benchmarking
8.4.8.4. Strategic initiatives
8.4.9. BioNTech SE
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product/service benchmarking
8.4.9.4. Strategic initiatives
8.4.10. BioCina
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product/service benchmarking
8.4.10.4. Strategic initiatives
8.4.11. Lonza
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product/service benchmarking
8.4.11.4. Strategic initiatives
8.4.12. Recipharm AB
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product/service benchmarking
8.4.12.4. Strategic initiatives
8.4.13. Novo Holdings (Catalent, Inc.)
8.4.13.1. Company overview
8.4.13.2. Financial performance
8.4.13.3. Product/service benchmarking
8.4.13.4. Strategic initiatives
8.4.14. Samsung Biologics
8.4.14.1. Company overview
8.4.14.2. Financial performance
8.4.14.3. Product/service benchmarking
8.4.14.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers